FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF C	CHANGES IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Lachey Jennifer					2. Issuer Name and Ticker or Trading Symbol Keros Therapeutics, Inc. [KROS]								neck all appl Direct	lationship of Reportir ck all applicable) Director Officer (give title		son(s) to Iss 10% Ov Other (s	ner	
	ROS THER	APEUTICS, IN		OINC E		3. Date of Earliest Transaction (Month/Day/Year) 02/11/2022								below	below) Chief Scien		below)	specify
(Street) LEXING	TON M		02421 (Zip)	DING E	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								e) X Form Form	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
(-19)				n-Deriv	/ative		·urit	ios Ac	· auirec	l Di	enosad o	of or Re	neficia	Ily Owne	d			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)		ction	Execution Date,		3. 4. Securitie		es Acquired (A) or Of (D) (Instr. 3, 4 and 5)		5. Amor Securit Benefic Owned	5. Amount of Securities Beneficially Owned Following Reported		n: Direct or Indirect onstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
							Code	v	Amount	(A) or (D)	Price	Transportion(s)				(111341.4)		
Common Stock 02/11		02/11/	2022	2022			M		2,650	A	\$0.3	88	3,350	D				
Common Stock		02/11/	/2022				S ⁽¹⁾		1,073	D	\$51.5	(2) 87	87,277		D			
Common Stock		02/11/	/2022				S ⁽¹⁾		1,378	D	\$52.35	5 ⁽³⁾ 85	5,899	D				
Common Stock C		02/11/	2022			S ⁽¹⁾		199	D	D \$53.1 ⁽⁴⁾		85,700		D				
		Т	able II								oosed of converti			y Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) of ative		ned on Date, Day/Year)	Code (II		of Der Sec Acc (A) Dis	posed D) tr. 3, 4	6. Date I Expiration (Month/I	on Da		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owner Form: Direct or Indi (I) (Ins	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$0.3	02/11/2022			M			2,650	(5)		03/25/2028	Common Stock	2,650	\$0.00	87,305	5	D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$50.97 to \$51.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$51.99 to \$52.805 inclusive.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$53.06 to \$53.17 inclusive.
- 5. Immediately exercisable.

Remarks:

/s/ Keith Regnante, Attorneyin-Fact

** Signature of Reporting Person

02/15/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.